Last reviewed · How we verify
NCT04455451
Intensive Care Therapy of Covid-19 Disease in Germany
trial in COVID in 2,054 participants. Completed in 30 September 2021.
15 August 2021
Quick facts
| Lead sponsor | University Hospital Tuebingen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,054 |
| Start date | 6 August 2020 |
| Primary completion | 15 August 2021 |
| Estimated completion | 30 September 2021 |
| Sites | 27 locations across Germany |
Conditions studied
Sponsor
University Hospital Tuebingen
Who can join
18 and older, any sex, with COVID or ARDS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Multi-center retrospective and prospective observational study of Covid-19 patients with severe or critical illness treated on a German ICU
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Machine learning identifies ICU outcome predictors in a multicenter COVID-19 cohort.
Magunia H, Lederer S, Verbuecheln R, Gilot BJ, et al · · 2021 · cited 42× · PMID 34404458 · DOI 10.1186/s13054-021-03720-4 -
Machine Learning Identifies ICU Outcome Predictors in a Multicenter COVID-19 Cohort.
Magunia H, Lederer S, Verbuecheln R, Gilot BJ, et al · · 2021 · DOI 10.21203/rs.3.rs-624809/v1
Verify or expand the search:
- PubMed search for NCT04455451
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID
Currently open trials in the same condition.
- NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
- NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
- NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
- NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
- NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting
Other University Hospital Tuebingen trials
Trials by the same sponsor.
- NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
- NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
- NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
- NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
- NCT07378891 — Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI) · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04455451 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
- Last refreshed: 12 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04455451.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing